Xanthoma is a dermatology condition characterized by fatty growth underneath the skin. The growth can vary in size ranging from a pinhead to as large as a grape and usually appear like a flat bump under the skin and sometimes yellow or orange colored. They usually don’t cause any pain with some minor irritation such as tenderness and itchy feeling.
There may be clusters of growths in the same area or several individual growths on different parts of the body. The exact causes of xanthoma is unknown, however, genetic factors have been indicated a cause of this conditions such as cogenosis type 1a, autosomal recessive hypercholesterolemia, alagille syndrome, and cholesterol storage disease.
The global xanthoma market is expected to reach USD 8.0 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.0 % during the forecast period 2017-2023.
Market Competitive
Some of the key players profiled in the report are
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Bayer HealthCare Pharmaceuticals LLC
- Pfizer Inc.
- Novartis International AG
- Teva pharmaceutical industries
- Novo Nordisk
- Sanofi and others.
Market Segments
The global market has been segmented on the basis of types, diagnosis, treatment, and end user.
Based on the types, the market has been segmented as xanthelasma, xanthoma tuberosum, xanthoma tendinosum, eruptive xanthoma, xanthoma planum, palmar xanthoma, tuberoeruptive xanthoma, and others.
Based on the diagnosis, the market has been segmented as physical examination, biopsy, blood tests, and others.
Based on the treatment, the market has been segmented as drugs, surgery, chemical treatment, and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.
Browse Complete Premium Report Details at: https://www.marketresearchfuture.com/reports/xanthoma-market-4860
Comments
Post a Comment